> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Trump Renews Call to Double Industry User Fees
- URL: https://www.fdaweb.com/trump-renews-call-to-double-industry-user-fees/
- Published: 2017-07-13T12:00:00.000Z
- Updated: 2026-09-14T22:34:06.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139129

The Trump Administration has renewed its call for Congress to double user fees paid by industry to help with the government’s budgetary activities. In a [statement](https://www.whitehouse.gov/the-press-office/2017/07/12/hr-2430-fda-reauthorization-act-2017?ref=fdaweb.com) following House passage ([see story](https://www.fdaweb.com/fda-user-fee-reauthorization-passes-house-on-voice-vote/)) of a user fee reauthorization bill (HR 2430), the White House said that to “better support FDA’s lifesaving mission while carefully spending taxpayer dollars, the president’s budget asks companies that benefit directly from FDA’s premarket review of medical products to finance 100% of FDA’s premarket review. In its current form, HR 2430 would require significant investment of taxpayer resources in FDA’s medical product review programs. The Administration urges the Congress to provide for 100% user fee funding within the reauthorized programs. In an era of renewed fiscal restraint, industries that benefit directly from FDA’s work should pay for it.”  
  
The Administration’s statement also said it was concerned with certain other provisions in the bill, “such as those providing additional market exclusivity to manufacturers, which could make exclusivity unpredictable and decrease competition. The Administration is committed to promoting the availability of generics in an efficient and effective manner that avoids unintended, adverse consequences. In addition, there are a number of important technical changes that the Administration seeks to make to the bill, including adjusting the foreign drug facility inspection fee.”